Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Exposure of BGF MDI HFO vs HFA with Spacer
NCT06297668Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Primary completion
- Jun 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of budesonide, glycopyrronium and formoterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Plasma Concentration-curve from Zero to the Last Quantifiable Concentration at Day 2 and Maximum Observed Concentration at Day 2. Started Apr 2024; status: completed.
02
Drugs
budesonideglycopyrroniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06297668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06297668.